In this Deep Dive Session, Dr. Johnny Mahlangu and Dr. Susan Louw discuss the evolution of hemophilia treatment, focusing on the transition from prophylaxis with factor replacement therapy to non-factor therapy and gene therapy. They delve into the challenges and benefits of these new therapies, including the need for different laboratory tests to monitor patients. The session also includes a detailed explanation by Dr. Louw on how to measure factor VIII and inhibitors in the presence of emicizumab.
Haem Deep Dive
02-12-2024 Duffy-null Associated Neutrophil Count – Diagnostically Easy, Therapeutically Challenging
December 2, 2024
